RxDoctor Payments Data

Aaron Rippelmeyer

Adult Health · Saint Louis, MONPI 1477911857

Payments from drug & device makers

$3,154in general payments, 2019–2025

Across 125 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$684
  • Novartis$538
  • Amgen$239
  • Actelion Pharmaceuticals US, Inc.$207
  • Boston Scientific$163
  • Boehringer Ingelheim$155
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,07497%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,154 in reported general payments places this provider in the 80th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$14,568
Medicare patients
141
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$174,065
EntrestoSacubitril/Valsartan203$155,304
JardianceEmpagliflozin81$93,068
Repatha SureclickEvolocumab30$25,023
Praluent PenAlirocumab26$20,657
FarxigaDapagliflozin Propanediol16$19,543
XareltoRivaroxaban19$15,778
Repatha PushtronexEvolocumab12$7,217
Icosapent Ethyl15$4,026
Midodrine Hcl33$2,505
Atorvastatin Calcium172$2,223
Metoprolol Succinate167$2,203
Rosuvastatin Calcium143$1,645
Ezetimibe58$1,382
Losartan Potassium116$1,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$174,065155 claims
NovartisEntresto$538$155,304203 claims
Boehringer IngelheimJardiance$155$93,06881 claims
AstraZenecaFarxiga$50$19,54316 claims
Johnson & JohnsonXarelto$141$15,77819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →